Who is sponsoring NCT07452523?

NCT07452523 is sponsored by Aymes International Limited.

What drugs are being tested in NCT07452523?

Interventions in NCT07452523: AYMES SWIFT oral nutritional supplement, AYMES SWIFT FIBRE, AYMES SWIFT PLANT.

What condition does NCT07452523 study?

NCT07452523 studies Disease Related Malnutrition.

Is NCT07452523 still recruiting?

NCT07452523 is currently active, enrolled. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT07452523

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerance, Palatability and Acceptability Evaluation of an Oral Nutrition Supplement

Active, enrolled NA Last updated 5 March 2026

What this trial tests

NA trial testing AYMES SWIFT oral nutritional supplement in Disease Related Malnutrition in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 October 2022

Primary endpoint
31 December 2025

1 December 2026

Quick facts

Lead sponsor	Aymes International Limited
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	1 October 2022
Primary completion	31 December 2025
Estimated completion	1 December 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

AYMES SWIFT oral nutritional supplement
AYMES SWIFT FIBRE
AYMES SWIFT PLANT

Conditions studied

Disease Related Malnutrition — all drugs for Disease Related Malnutrition →

Sponsor

Aymes International Limited — full company profile →

Who can join

18 and older, any sex, with Disease Related Malnutrition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the tolerance (gastrointestinal) and acceptability of a new Oral Nutrition Supplement in patients with or at risk of disease related malnutrition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Aymes International Limited trials

Trials by the same sponsor.

NCT04703881 — Tolerance and Acceptability Evaluation AYMES ActaGain · NA · completed
NCT04703894 — Tolerance and Acceptability Evaluation AYMES Cardiff · NA · completed
NCT04700293 — Tolerance and Acceptability Evaluation of AYMES AMSTERDAM · NA · completed
NCT03844373 — Tolerance and Acceptability Evaluation of STOCKHOLM · NA · completed
NCT03836274 — Tolerance and Acceptability Evaluation of MONACO · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07452523 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aymes International Limited
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07452523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing